Are we studying and treating schizophrenia correctly?
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
New findings are rapidly revealing an increasingly detailed image of neural - and molecular-level dysfunction in schizophrenia, distributed throughout interconnected cortico-striato-pallido-thalamic circuitry. Some disturbances appear to reflect failures of early brain maturation, that become codified into dysfunctional circuit properties, resulting in a substantial loss of, or failure to develop, both cells and/or appropriate connectivity across widely dispersed brain regions. These circuit disturbances are variable across individuals with schizophrenia, perhaps reflecting the interaction of multiple different risk genes and epigenetic events. Given these complex and variable hard-wired circuit disturbances, it is worth considering how new and emerging findings can be integrated into actionable treatment models. This paper suggests that future efforts towards developing more effective therapeutic approaches for the schizophrenias should diverge from prevailing models in genetics and molecular neuroscience, and focus instead on a more practical three-part treatment strategy: 1) systematic rehabilitative psychotherapies designed to engage healthy neural systems to compensate for and replace dysfunctional higher circuit elements, used in concert with 2) medications that specifically target cognitive mechanisms engaged by these rehabilitative psychotherapies, and 3) antipsychotic medications that target nodal or convergent circuit points within the limbic-motor interface, to constrain the scope and severity of psychotic exacerbations and thereby facilitate engagement in cognitive rehabilitation. The use of targeted cognitive rehabilitative psychotherapy plus synergistic medication has both common sense and time-tested efficacy with numerous other neuropsychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia
Walsh, T., McClellan, J. M., McCarthy, S. E., Addington, A. M., Pierce, S. B., Cooper, G. M., Nord, A. S., Kusenda, M., Malhotra, D., Bhandari, A., et al. (2008) · Science · doi:10.1126/science.1155174 · Cited by 1,800
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Baxter, L. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820090009002 · Cited by 1,293
Schizophrenia as a Disorder of Neurodevelopment
Lewis, D. A., & Levitt, P. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142754 · Cited by 1,163
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909 · cited 2×
“…circuitry that could be recruited to enhance the effectiveness of CT. Memantine is neuroprotective (Kornhuber et al., 1994; Rogawski and Wenk, 2003; Lipton, 2006), enhances cortical metabolic efficiency (Willenborg et al., 2011), is well-tolerated by schizophrenia patients (Krivoy et al., 2008;…”
A functional neuroanatomy of hallucinations in schizophrenia
Silbersweig, D. A., Stern, E., Frith, C., Cahill, C., Holmes, A., Grootoonk, S., Seaward, J., McKenna, P., Chua, S. E., Schnorr, L., et al. (1995) · Nature · doi:10.1038/378176a0 · Cited by 906 · cited 1×
“…abnormalities are reported (and not, for example, areas activated abnormally under experimental or symptomatic conditions (Dolan et al., 1995; Silbersweig et al., 1995; Heckers et al., 1998; Volz et al., 1999; Kumari et al., 2003; cf. Brown and Thompson, 2010; Heckers and Konradi, 2010)).”
Bogerts, B. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790310046006 · Cited by 880
Prenatal developmental disturbances in the limbic allocortex in schizophrenics
Jakob, H., & Beckmann, H. (1986) · Journal of Neural Transmission · doi:10.1007/bf01249090 · Cited by 875 · cited 4×
“…1986; Seidman et al., 2003; Prasad et al., 2004; Jung et al., 2009 Superior temporal gyrus Matsumoto et al., 2001; Jung et al., 2009 Insula Jakob and Beckmann, 1986; Ellison-Wright et al., 2008, Amygdala Joyal et al., 2003; Ellison-Wright et al., 2008; Bhojraj et al., 2011 Superior…”
InfluentialMorrison, A. P., French, P., Walford, L., Lewis, S. W., Kilcommons, A., Green, J., Parker, S., & Bentall, R. P. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.4.291 · Cited by 740
Impaired recruitment of the hippocampus during conscious recollection in schizophrenia
Heckers, S., Rauch, S., Goff, D., Savage, C., Schacter, D., Fischman, A., & Alpert, N. (1998) · Nature Neuroscience · doi:10.1038/1137 · Cited by 570 · cited 3×
“…abnormalities are reported (and not, for example, areas activated abnormally under experimental or symptomatic conditions (Dolan et al., 1995; Silbersweig et al., 1995; Heckers et al., 1998; Volz et al., 1999; Kumari et al., 2003; cf. Brown and Thompson, 2010; Heckers and Konradi, 2010)).”
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
BEASLEY, C., & REYNOLDS, G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00122-3 · Cited by 426
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419 · cited 1×
“Trials of potential pro-cognitive agents in schizophrenia yielding negative results were not conducted within the context of systematic cognitive interventions (cf. Goff et al., 1996, 1999, 2007; Buchanan et al., 2007; Green, 2007; Goff et al., 2008; Barch, 2010).”
Mismatch Negativity Deficits Are Associated With Poor Functioning in Schizophrenia Patients
Light, G. A., & Braff, D. L. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.127 · Cited by 407 · cited 2×
“In addition to PPI, memantine challenge in healthy subjects enhances other markers of CSPT and functional deficits in schizophrenia, includingmismatch negativity (Light and Braff, 2005; Korostenskaja et al., 2007), and in preliminary studies appears to increase WM performance in some individuals (Swerdlow et al.”
Neural Mechanisms of a Genome-Wide Supported Psychosis Variant
Esslinger, C., Walter, H., Kirsch, P., Erk, S., Schnell, K., Arnold, C., Haddad, L., Mier, D., Opitz von Boberfeld, C., Raab, K., et al. (2009) · Science · doi:10.1126/science.1167768 · Cited by 400
Swerdlow, N. R., Light, G. A., Cadenhead, K. S., Sprock, J., Hsieh, M. H., & Braff, D. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1325 · Cited by 339 · cited 3×
“PPI is regulated by CSPT circuitry (cf. Swerdlow et al., 2008), reduced in schizophrenia patients (Braff et al., 1978; Swerdlow et al., 2006a) and correlated with CT-relevant executive functions including WM (Bitsios et al., 2006; Giakoumaki et al., 2006; van der Linden et al., 2006; Light et al.,…”
Self-citationEack, S. M., Greenwald, D. P., Hogarty, S. S., Cooley, S. J., DiBarry, A. L., Montrose, D. M., & Keshavan, M. S. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1468 · Cited by 289 · cited 2×
“, 2009; Medalia and Choi, 2009), with sustained benefits often lasting years (e.g. Granholm et al., 2007; Sellwood et al., 2007; Eack et al., 2009; McGurk et al., 2009).”
Effects of environment on morphology of rat cerebral cortex and hippocampus
Diamond, M. C., Ingham, C. A., Johnson, R. E., Bennett, E. L., & Rosenzweig, M. R. (1976) · Journal of Neurobiology · doi:10.1002/neu.480070108 · Cited by 192 · cited 2×
“, 2009), and draw from substantial preclinical and clinical data supporting the benefits of environmental enrichment on neural development, cognitive function (Diamond et al., 1976; Hack et al., 1995; Briones et al., 2009; Sweatt, 2009) and the creation of a protective “cognitive reserve” (Dhanushkodi and Shetty, 2008…”
Orbitofrontal volume deficit in schizophrenia and thought disorder
Nakamura, M., Nestor, P. G., Levitt, J. J., Cohen, A. S., Kawashima, T., Shenton, M. E., & McCarley, R. W. (2007) · Brain · doi:10.1093/brain/awm265 · Cited by 186
Koo, M.-S., Levitt, J. J., Salisbury, D. F., Nakamura, M., Shenton, M. E., & McCarley, R. W. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.7.746 · Cited by 175
for the MEM-MD-29 Study Group, Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., & Gage, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.200 · Cited by 162 · cited 4×
“, 2011), is well-tolerated by schizophrenia patients (Krivoy et al., 2008; Zdanys and Tampi, 2008; de Lucena et al., 2009; Lieberman et al., 2009) and has been safely used in large numbers of patients, including elderly, frail clinical populations (cf.”
InfluentialTomasi, D., Volkow, N. D., Wang, G. J., Wang, R., Telang, F., Caparelli, E. C., Wong, C., Jayne, M., & Fowler, J. S. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.060 · Cited by 145 · cited 1×
“1) (Swerdlow et al., 2010; Tomasi et al., 2011).”
GOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144 · cited 2×
“Trials of potential pro-cognitive agents in schizophrenia yielding negative resultswere not conductedwithin the context of systematic cognitive interventions (cf. Goff et al., 1996, 1999, 2007; Buchanan et al., 2007; Green, 2007; Goff et al., 2008; Barch, 2010).”
Kessler, R. M., Woodward, N. D., Riccardi, P., Li, R., Ansari, M. S., Anderson, S., Dawant, B., Zald, D., & Meltzer, H. Y. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.029 · Cited by 136 · cited 2×
“Studies also document abnormalities in the number or distribution of neurotransmitter receptors in theseandotherbrain regions,whichmay reflect aprimary loss of cells that support them, a secondary response to abnormalities of the fibers that innervate them or the chemicals they deliver, or combinations thereof (cf. Le…”
Cited by
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Nonhuman primate model of schizophrenia using a noninvasive EEG method
Gil-da-Costa, R., Stoner, G. R., Fung, R., & Albright, T. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312264110 · Cited by 182
Acheson, D. T., Twamley, E. W., & Young, J. W. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00103 · Cited by 26
The Neuropsychiatric Translational Revolution: Still Very Early and Still Very Challenging
Braff, L., & Braff, D. L. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2184 · Cited by 20
Metadata
- Authors
- Swerdlow, N. R.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 130
- Issue
- 1-3
- Pages
- 1-10
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2080380962
- Cited by
- 76
- References
- 25
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.